CD8A and neoplasm: Immune effector cells assays demonstrated that the number of tumor-infiltrated CD8+ T and NK cells in mice treated with αNKG2A-N215 (12 μg) was 3–4 times greater than that in mice treated with αNKG2A + N215 (12 μg) (Figure 5(D)).